CombiMatrix Molecular Diagnostics announced this week that it has launched its BAC HD Scan test, after having completed clinical validation of the diagnostic.
The company said the high-density constitutional array genetic test is based on its Bacterial Artificial Chromosome array technology, and is comprised of 2,437 unique validated loci obtained through the company's partnership with Toronto-based Center of Applied Genomics.
“The new test is designed to interrogate specific genes and genomic regions associated with over 125 known genetic disorders while enabling screening for unexpected abnormalities with an industry-best average resolution of 432 kb across the entire genome,” the company said in a statement. The array also incorporates the probe content of CombiMatrix's recently launched ATScan for Autism Spectrum Disorder.
"One of the major advantages of our testing is that it enables the evaluation of thousands of genomic regions simultaneously while requiring no prior knowledge of what kind of abnormalities may be present in a patient — essentially, it can act as a screen for genomic abnormalities,” Mercedes Gorre, CombiMatrix Molecular Diagnostics VP of scientific affairs, said in a statement.
The list of 125 disorders can be reviewed here.